Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis | Zendy

Dominique Baeten | Zendy; Joachim Sieper | Zendy; J. Braun | Zendy; Xenofon Baraliakos | Zendy; Maxime Dougados | Zendy; Paul Emery | Zendy; Atul Deodhar | Zendy; Brian Porter | Zendy; Ruvie Martin | Zendy; Mats Andersson | Zendy; Shephard Mpofu | Zendy; Hanno B. Richards | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Author(s) -

Dominique Baeten,

Joachim Sieper,

J. Braun,

Xenofon Baraliakos,

Maxime Dougados,

Paul Emery,

Atul Deodhar,

Brian Porter,

Ruvie Martin,

Mats Andersson,

Shephard Mpofu,

Hanno B. Richards

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1505066

Subject(s) - secukinumab , ankylosing spondylitis , medicine , monoclonal antibody , spondylitis , monoclonal , clinical trial , immunology , antibody , arthritis , psoriatic arthritis

Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in patients with active ankylosing spondylitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research